Research Overview
Decoy receptor design
Membrane ActRIIB transduces signals from myostatin, activin A, GDF-11 and several BMPs into SMAD2/3 phosphorylation, a pathway that restrains skeletal-muscle accretion. ACE-031 presents the same ligand-binding surface in soluble form, so ligands are captured before they reach the cell. Fusing that domain to IgG1 Fc achieves two things at once: it produces the dimeric geometry the natural receptor uses, and it recruits FcRn-mediated recycling, which is what gives Fc fusions their characteristically long persistence relative to isolated domains.
What research has examined
- Increases in lean mass and muscle fibre cross-sectional area reported in rodent models after ActRIIB-Fc administration.
- Dystrophic mouse models, where the construct was assessed for effects on muscle function as well as mass.
- Bone-density endpoints, since activin signalling also influences bone remodelling.
- Comparative studies against follistatin and anti-myostatin antibodies, which block the same axis at different points.
Selectivity as the central question
Because ACE-031 traps everything that binds ActRIIB rather than myostatin alone, its potency and its off-target profile share the same origin. Much of the subsequent literature in this area concerns engineering narrower traps that retain muscle effects without the vascular findings, and ACE-031 is frequently the benchmark those constructs are measured against.
